Hepatitis B Virus Infection Seromarkers Among College Freshmen and Their Immune Responses to Different Vaccination Policies of Hepatitis B Vaccine

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2021 Aug 18

PMID 34407383

Citations 3

Authors

Yuyang Xu

Yan Liu

Jun Wang

Xinren Che

Xuechao Zhang

Wei Jiang

Jian Du

Xiaoping Zhang

Wenwen Gu

Affiliations

Soon will be listed here.

Abstract

Background: College students are one of the susceptible population of Hepatitis B virus (HBV) infection. We aim to delineate HBV infection seromarkers among college freshmen and to evaluate immunological response of vaccination immunization for hepatitis B vaccine (HepB).

Methods: A simple random sampling method was adopted to select subjects and who met the "inclusion and exclusion criteria" and who with history of vaccination were selected as the observation objects. HBsAg and anti-HBs levels were detected before revaccination. Subjects with negative anti-HBs before immunization were inoculated with 20 ug HepB according to the 0-1-6 procedure and those with weak positive anti-HBs before immunization were inoculated with 1-dose 20 ug HepB. Anti-HBs levels were detected after HepB booster. Combined with the results of anti-HBs, their immune response to HepB and influencing factors in freshmen were investigated. Anti-HBs before immunization was negative and ≥10 m IU/ml after immunization was considered positive conversion; anti-HBs before immunization was weak positive and anti-HBs≥100 m IU/ml after immunization was also considered positive conversion.

Results: A total of 10645 freshmen were included. The total rate of HBsAg carriers was 0.6% (63/10645), and the strong positive rate of anti-HBs was 16.1% (1706/10645), the weak positive rate was 14.4% (1526/10645).1286 freshmen were vaccinated with HepB and completed the questionnaire survey. About 79.0% (154/195) of freshmen's anti-HBs turned strong positive after receiving 1-dose HepB and 100.0% (1091/1091) turned positive after receiving 3-doses HepB. The Geometrical Mean Titer (GMT) of anti-HBs was significantly influenced by gender, registration and the immunization doses of HepB.

Conclusion: The HBsAg carrying rate and anti-HBs positive rate of college freshmen were low, and the HepB has a good effect on the immunity of college freshmen. Increasing the immunization rate of HepB is very important for the prevention and control of hepatitis B.

Citing Articles

Seroprevalence of hepatitis B among the general population in Shandong Province, Eastern China, an update 30 years after the implementation of the neonatal vaccination program.

Yan B, Zhang X, Lv J, Feng Y, Meng X, Lin X BMC Infect Dis. 2024; 24(1):1433.

PMID: 39695996 PMC: 11653818. DOI: 10.1186/s12879-024-10340-0.

Identification of associated risk factors for serological distribution of hepatitis B virus via machine learning models.

Yao N, Liu Y, Xu J, Wang Q, Zhou Q, Wang Y BMC Infect Dis. 2024; 24(1):66.

PMID: 38195403 PMC: 10775609. DOI: 10.1186/s12879-023-08911-8.

Analysis of Knowledge, Attitude and Practice of Hepatitis B Among Freshmen in Jiangsu Based on Lasso-Logistic Regression and Structural Equation Model.

Tu F, Yang R, Wang W, Li R, Du G, Liu Y Infect Drug Resist. 2022; 15:3063-3073.

PMID: 35734538 PMC: 9207125. DOI: 10.2147/IDR.S365728.

References

. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018; 3(6):383-403. DOI: 10.1016/S2468-1253(18)30056-6. View

Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H . Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol. 2017; 5(4):297-318. PMC: 5719188. DOI: 10.14218/JCTH.2016.00019. View

Shen L, Wang F, Wang F, Cui F, Zhang S, Zheng H . Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China. Vaccine. 2012; 30(47):6623-7. DOI: 10.1016/j.vaccine.2012.08.067. View

Wu T, Lin H, Wang L . Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology. 2012; 57(1):37-45. DOI: 10.1002/hep.25988. View

Zhang W, Lin C, Han L, Li L, Gao P, Lin H . [Study on the immuno-effects and influencing factors of Chinese hamster ovary (CHO) cell hepatitis B vaccine among adults, under different dosages]. Zhonghua Liu Xing Bing Xue Za Zhi. 2010; 31(7):767-70. View

Chung P, Suen S, Chan O, Lao T, Leung T . Awareness and knowledge of hepatitis B infection and prevention and the use of hepatitis B vaccination in the Hong Kong adult Chinese population. Chin Med J (Engl). 2012; 125(3):422-7. View

Wang Z, Gao Y, Wang P, Wei L, Xie C, Yang Z . Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study. Hum Vaccin Immunother. 2018; 14(6):1475-1482. PMC: 6037445. DOI: 10.1080/21645515.2018.1438090. View

Lao T, Sahota D, Chan P . Three decades of neonatal vaccination has greatly reduced antenatal prevalence of hepatitis B virus infection among gravidae covered by the program. J Infect. 2018; 76(6):543-549. DOI: 10.1016/j.jinf.2018.04.003. View

Cui F, Shen L, Li L, Wang H, Wang F, Bi S . Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerg Infect Dis. 2017; 23(5):765-772. PMC: 5403029. DOI: 10.3201/eid2305.161477. View

10.

Ni Y, Chang M, Wu J, Hsu H, Chen H, Chen D . Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012; 57(4):730-5. DOI: 10.1016/j.jhep.2012.05.021. View

11.

Cassidy W, Watson B, Ioli V, Williams K, Bird S, West D . A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics. 2001; 107(4):626-31. DOI: 10.1542/peds.107.4.626. View

12.

Yue X, Ge C, Zhuge S, He H, Yang H, Xu H . Changes and analysis of anti-HBs titres after primary immunization in 1- to 16-year-old Chinese children: A hospital-based study. J Viral Hepat. 2017; 25(4):373-380. DOI: 10.1111/jvh.12818. View

13.

Liu M, Sheng Y, Liu J, Hu H, Zhang Q, Ren H . Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis. Ann Saudi Med. 2013; 33(2):169-76. PMC: 6078630. DOI: 10.5144/0256-4947.2013.169. View

14.

Zhao Y, Han B, Zhang X, Pan L, Zhou H, Gao Z . Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination. BMC Infect Dis. 2019; 19(1):482. PMC: 6543564. DOI: 10.1186/s12879-019-4134-9. View